Inspire Medical Systems is a medical technology company that treats obstructive sleep apnea through an implantable device that stimulates the airway. It generated $803 million in revenue in 2024, a 28% increase over the previous year, and reached over 90,000 total patients. The company recently turned profitable on a full-year basis, ending 2024 with $53.5 million in net income and maintaining exceptionally high gross margins above 84%.
The investment thesis on Inspire Medical Systems is that it owns the only viable surgical alternative for the millions of sleep apnea patients who cannot tolerate traditional masks, creating a high-margin monopoly in a massive market. While CPAP machines remain the first line of treatment, roughly one-third of patients stop using them, leaving a huge population with no other effective option until Inspire. The thesis breaks if newer weight-loss drugs like GLP-1s reduce the need for surgical sleep apnea intervention.
We believe Inspire is a rare growth business that has already cleared the hardest hurdles: proving its clinical value and turning GAAP profitable. Its massive gross margins and clean balance sheet provide a safety net that most mid-cap medical device companies lack. The swing factor will be how effectively management defends its market share as more investors focus on the potential impact of obesity drugs on sleep apnea.
Inspire Medical Systems's stock has crashed over the last few years and currently sits down about 85% from where it was five years ago. Even though the company is finally making a profit and offers a unique implant for sleep apnea patients, investors have turned away, causing the price to drop steadily.
What does it do?
Inspire Medical Systems is a growth-stage medical device business that earns money by selling an implantable neurostimulation system for obstructive sleep apnea. Unlike traditional CPAP machines that blow air through a mask, the Inspire system is a small device placed under the skin during a short outpatient procedure. It monitors the patient's breathing and delivers mild stimulation to the tongue muscles, keeping the airway open during sleep. The company sells the physical components—the stimulator, the sensing lead, and the stimulation lead—directly to hospitals and surgery centers.
Where does revenue come from?
Almost all revenue comes from the sale of the Inspire system components and the handheld sleep remote given to each patient. The company generates over 95% of its sales in the United States, where it has built a specialized sales force to train surgeons and work with sleep clinics. International sales, primarily in Europe and Japan, represent less than 5% of the business but are a growing focus for expansion.
Revenue by Geography
Who are its customers?
Inspire Medical Systems serves over 1,575 medical centers and has treated more than 90,000 patients as of the end of 2024. The direct customers are the hospitals and ambulatory surgery centers that purchase the hardware for surgical implantation. However, the company’s success depends on two other groups: the Ear, Nose, and Throat (ENT) surgeons who perform the procedures and the sleep physicians who refer patients. To reach these users, Inspire spends heavily on direct-to-consumer advertising, which drives patients to its website where they are connected to one of the 300 centers using its digital scheduling tool.
What gives it staying power?
Inspire has a massive competitive lead because its system is the only FDA-approved neurostimulation therapy for sleep apnea backed by a decade of clinical data. The high regulatory barrier to entry and the specialized training required for surgeons make it very difficult for new competitors to displace them.
Where is it headed?
The company is focusing on launching Inspire V, a next-generation device that simplifies the surgery by removing the need for a separate pressure sensor lead. Management expects this to make the procedure faster and more appealing to surgeons. If successful, this could significantly increase the number of procedures each medical center can perform per day.
Verdict: The business has successfully transitioned from a high-burn startup to a profitable, self-sustaining growth engine. Revenue grew 28% to $803 million in 2024, and the company has delivered its first full year of positive net income. This growth is exceptionally high quality because it is backed by gross margins that have consistently stayed above 84%.
Verdict: Cash generation is strong and tracks actual earnings, allowing the company to fund its own growth. Free cash flow turned positive at $90 million in 2024, a significant jump from being flat in 2023. This means Inspire is no longer dependent on issuing new stock or taking on debt to pay for its massive direct-to-consumer marketing campaigns.
Verdict: The balance sheet is pristine, with no meaningful debt and over $500 million in cash. Having a debt-to-equity ratio of only 0.04x gives the company total flexibility to invest in new products or expand internationally. This massive cash pile also acts as a shield if the company decides to acquire smaller technology partners to enhance its software or hardware.
Inspire Medical Systems is in its strongest financial position ever. The combination of 28% revenue growth and 85% gross margins with a clean balance sheet makes it a standout in the medical device sector. Inspire has proven it can grow fast while making real money.
Profitability has arrived much faster than expected, with net income reaching $53.5 million for the full year 2024. The company is proving it can scale its revenue at 28% without needing to grow its operating expenses at the same rate.
A potential slowdown in procedure growth as the market for "easy" CPAP failures gets more competitive. While revenue is still growing fast, any sustained drop below 15% would signal that the obesity drug threat or market saturation is finally having an impact.
The obstructive sleep apnea (OSA) market is estimated to be worth over $10 billion globally and is growing at double digits. Inspire operates in a sub-sector of the market serving the millions of patients who cannot tolerate CPAP masks, which are the standard $500 to $1,000 devices. While the industry has been dominated by air-pressure machines for decades, surgical neurostimulation has emerged as the only high-efficacy alternative. Inspire is currently the undisputed leader in this surgical niche, with a runway that extends to the estimated 30 million people in the U.S. who suffer from sleep apnea.
The competitive dynamic is characterized by high barriers to entry due to a decade of clinical data and strict FDA Pre-Market Approval requirements. While CPAP manufacturers compete fiercely on price and logistics, Inspire currently has no direct FDA-approved surgical competitor in the United States. This allows for exceptional pricing power and structural margins.
The main threat comes from CPAP leaders like ResMed, which are trying to improve mask comfort to prevent patients from failing therapy and seeking a surgical alternative. Nyxoah is the most dangerous direct threat as it nears potential FDA approval for a competing neurostimulation system. Other large medical device companies have tried to enter this space but have largely failed or abandoned their clinical programs due to the complexity of the surgery and patient monitoring.
Inspire is currently holding its ground with a near-monopoly on the neurostimulation market. Its 28% revenue growth in 2024 suggests it is still winning share from the pool of CPAP failures faster than competitors can enter the space.
Inspire’s moat is built on a massive "moat of data" and its unique FDA Pre-Market Approval (PMA) status. It has treated 90,000 patients and published multiple long-term clinical trials that prove its device works safely over five years. No other company can offer physicians or insurers that same level of certainty today.
The company’s 86% gross margin and 18% return on equity prove that its advantage is real and not just a result of a hot market. These numbers are typical of a high-margin monopoly and show that Inspire does not have to cut prices to win business. The specialized training required for 1,500+ surgical centers also creates a "soft" switching cost for the medical community.
The moat is currently stable but faces a long-term challenge from both new device competitors and the potential for weight-loss drugs to reduce the total market size. The verdict rests on whether Inspire V can further widen the gap before Nyxoah reaches the market.
Led the company from startup to $803M revenue and full GAAP profitability in 2024.
Grew cash to $516M by end of 2024 without taking on significant debt.
Founder-CEO Timothy Herbert holds a multi-million dollar stake and has led since inception.
Capital Allocation Track Record
Management quality is exceptional, evidenced by their ability to transition the company from a loss-making R&D shop to a profitable enterprise with $157 million in adjusted EBITDA. CEO Timothy Herbert has maintained a remarkably consistent strategy for over a decade, focusing on clinical data first and sales second. This patient approach has earned the trust of the medical community and insurers, which is the hardest asset to build in healthcare. They have managed the company's cash with extreme discipline, avoiding dilutive raises even during the market downturn of 2022.
The primary governance risk is the high level of dependence on Timothy Herbert, who has been the singular driving force behind the company's culture and strategy. While the company has a credible bench, including CFO Matthew Osberg, the "founder-CEO" premium is significant here. There is no dual-class share structure, meaning the board is fully independent and accountable to shareholders. The company’s clear communication and history of hitting guidance have built a strong reservoir of credibility with institutional investors.
We expect revenue to grow from $0.8B in FY2026 to $1.4B in FY2031 (~10% CAGR), with EPS growing from $0.90 to $5.77 (~45% CAGR). Growth is driven by the continued adoption of the Inspire system as the primary surgical alternative for patients who cannot tolerate CPAP therapy. Operating margins expand as the company leverages its specialized sales force and fixed manufacturing costs over a growing volume of implant procedures. EPS grows Operating margin expected to reach ~25% by FY2031.
Launch of Inspire V simplifies the surgical procedure significantly. A faster, two-incision surgery instead of three will allow doctors to perform more implants per day.
International expansion in Japan and Europe reaches meaningful scale. Moving beyond the U.S. market would double the addressable patient population over the next five years.
Broader insurance coverage for pediatric and low-BMI patient groups. Expanding the FDA label to include more patient types opens up entirely new revenue streams.
GLP-1 weight-loss drugs reduce the severity of sleep apnea. If a significant portion of the target population loses enough weight to cure their apnea, the referral funnel shrinks.
FDA approval of direct neurostimulation competitors like Nyxoah. The arrival of a second player would likely end Inspire's monopoly and put pressure on its 85% gross margins.
Slowdown in hospital capital spending or elective surgery volume. Economic pressure on surgery centers could lead to a temporary drop in new center openings or procedure counts.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to next year's earnings) as our primary framework. It fits Inspire because the company has successfully crossed the threshold into GAAP profitability, making earnings a more reliable signal of value than the revenue multiples used for earlier-stage medical device startups.
Next year's projected EPS of $1.27 multiplied by a 45x multiple gives a per-share fair value of $57. A 45x multiple sits in the middle of the high-growth med-tech range—below Intuitive Surgical (62x) but above Edwards Lifesciences (31x)—reflecting Inspire's superior gross margins balanced against current regulatory uncertainty. We use the FY2027 EPS of $1.27 from the deterministic engine to reflect a full year of normalized operations after the current coding and WISeR program disruptions are fully implemented.
A 5-year Discounted Cash Flow (DCF) cross-check produces a long-term fair value of $105, which is significantly higher than our $57 Forward P/E target. This 84% disagreement is expected: the DCF captures the massive earnings compounding projected through 2031 ($5.77 EPS), whereas a Forward P/E is a 12-month snapshot of a company currently navigating a trough. We trust the $57 figure for immediate valuation but view the $105 DCF as the ultimate "intrinsic value" if management successfully executes the five-year growth plan.
We're assuming the current coding and reimbursement disruption is a temporary 12-to-18-month headwind rather than a permanent loss of pricing power. While the -52 modifier has caused near-term "hand-wringing" among physicians, the clinical superiority of the Inspire V system and the lack of viable CPAP alternatives for this patient cohort support a return to normalized growth by FY2027.
We're assuming Inspire maintains its industry-leading gross margins above 85%. The company has successfully sustained these margins throughout its scaling phase, and the transition to the Inspire V system provides further manufacturing efficiencies that protect the bottom line even if volume growth temporarily slows.
We're assuming the Obstructive Sleep Apnea (OSA) surgical market remains underserved with a massive 5-year runway. Even with the rise of medical weight-loss treatments, the millions of patients who cannot tolerate CPAP machines represent a multi-billion dollar opportunity that Inspire currently dominates with a wide competitive moat.
The biggest risk is that weight-loss drugs (GLP-1s) structurally reduce the addressable market for sleep apnea surgery over the next five years. This would lower long-term growth expectations and compress the forward multiple from 45x to 25x, knocking approximately $25 off the per-share fair value. Watch quarterly surgical volume guidance for any commentary suggesting a shrinking new-patient funnel.
Bear case ($38): Revenue growth remains below 5% for three consecutive quarters due to physician pushback on new coding modifiers; or GLP-1 weight-loss drug data shows a definitive 25%+ reduction in the surgical-eligible patient population.
Bull case ($82): CMS issues a favorable reimbursement clarification that reverses the current physician pay headwinds by early 2027; or Inspire V adoption reaches 75% of the sales mix by year-end, driving higher ASPs and operating leverage.
Clearthesis wrote this report from 36 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning neutral because Inspire has successfully proven its surgical sleep apnea device can reach profitability while sustaining high demand. The company reached over 90,000 patients and generated $803 million in annual revenue by capturing people who cannot use standard masks. Its 84 percent gross margin confirms the business model works.
Skeptics think that Inspire is running out of new patients who are willing to undergo an invasive surgery. As the pool of easy-to-convince patients shrinks, the company must spend significantly more on marketing and physician training to sustain its growth, which threatens to eat into its thin net income.